Skip to main content
SpringerLink
Log in

Anti-angiogenesis Therapy as an Adjunct to Chemotherapy in Oncology

  • Chapter
  • First Online:
Angiogenesis Modulations in Health and Disease

  • 836 Accesses

Abstract

On November 18th 2011, the FDA announced the anticipated removal of Avastin’s (bevacizumab) indication for metastatic breast cancer based on the lack of evidence supporting its use for the improvement of overall survival. Avastin, much like other anti-angiogenic therapies, has been shown to slow but not prevent metastasis when given in combination with chemotherapy. An anti-angiogenic therapy that targets multiple pro-angiogenic factors is the focus of much research. In this chapter we present the anti-angiogenesis therapies available, obstacles to the prevention of tumor neovascularization, and finally delve into new therapies showing results that may change the future of oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. SEER Cancer Statistics Review (1975–2008) National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed 12 Mar 2013

  2. American Cancer Society Cancer Facts and Figures (2012) American Cancer Society. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012. Accessed 12 Mar 2013

  3. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11(11):3974–3986

    Article  PubMed  CAS  Google Scholar 

  4. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247

    Article  PubMed  CAS  Google Scholar 

  5. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O’Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260

    Article  PubMed  CAS  Google Scholar 

  6. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC, Seagroves TN (2012) Hypoxia inducible factor-1 alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14(1):R6

    Article  PubMed  CAS  Google Scholar 

  7. Mooring SR, Jin H, Devi NS, Jabbar AA, Kaluz S, Liu Y, Van Meir EG, Wang B (2011) Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem 54(24):8471–8489

    Article  PubMed  CAS  Google Scholar 

  8. Birner P, Schindl M, Obermair A, Plank C (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693–4696

    PubMed  CAS  Google Scholar 

  9. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100(6):971–978

    Article  PubMed  CAS  Google Scholar 

  10. Karar J, Maity A (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4:51

    Article  PubMed  CAS  Google Scholar 

  11. Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9(2):267–285

    Article  PubMed  CAS  Google Scholar 

  12. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

    Article  PubMed  CAS  Google Scholar 

  13. FDA Begins Process to Remove Breast Cancer Indication From Avastin Label (2010) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm237172.htm. Accessed 12 Mar 2013

  14. Montero AJ, Avancha K, Gluck S, Lopes G (2012) A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 132(2):747–751

    Google Scholar 

  15. Genentech Inc (2013) Avastin prescribing information. http://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed 12 Mar 2013

  16. Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23(5):289–304

    Article  PubMed  CAS  Google Scholar 

  17. Regeneron Pharmaceuticals Inc (2013) Eylea prescribing information. http://www.regeneron.com/Eylea/eylea-fpi.pdf. Accessed 12 Mar 2013

  18. Sanofi-Aventis (On going phase III trial) (2013) A multinational, randomized, double-blind study, comparing the efficacy of aflibercept once every 2 weeks versus placebo in patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5-FU combination (FOLFIRI) after failure of an oxaliplatin based Regimen. http://clinicaltrials.gov/ct2/show/NCT00561470?term=velour&rank=1. Accessed 12 Mar 2013

  19. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557–3565

    Article  PubMed  CAS  Google Scholar 

  20. Amgen (On going phase III trial) (2013) A phase 3 randomized, double-blind, placebo-controlled, multicenter study of AMG 386 with paclitaxel and carboplatin as first-line treatment of subjects with FIGO stage III-IV epithelial ovarian, primary peritoneal or fallopian tube cancers. http://clinicaltrials.gov/ct2/show/NCT01493505?term=trinova-3&rank=1. Accessed 12 Mar 2013

  21. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780–787

    Article  PubMed  CAS  Google Scholar 

  22. Yu L, Liang XH, Ferrara N (2011) Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 408(2):276–281

    Article  PubMed  CAS  Google Scholar 

  23. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J Jr, Schwartz D, Kreuter J, von Briesen H, Langer K (2010) Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31(8):2388–2398

    Article  PubMed  CAS  Google Scholar 

  24. Pfizer Labs Inc (2012) Sutent prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=607. Accessed 12 Mar 2013

  25. Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A (2010) Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28(6):866–875

    Article  PubMed  CAS  Google Scholar 

  26. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  PubMed  CAS  Google Scholar 

  27. Bayer Healthcare Pharmceuticals Inc., Onxy Pharmaceuticals (2012) Nexavar prescribing information. http://www.nexavar-us.com/scripts/pages/en/patient/index.php. Accessed 12 Mar 2013

  28. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312–3318

    Article  PubMed  CAS  Google Scholar 

  29. Astra Zeneca Pharmaceuticals (2011) Caprelsa prescriber information. http://www1.astrazeneca-us.com/pi/caprelsa.pdf. Accessed 12 Mar 2013

  30. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767–772

    Article  PubMed  CAS  Google Scholar 

  31. GlaxoSmithKline (2009) Votrient prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf. Accessed 12 Mar 2013

  32. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068

    Article  PubMed  CAS  Google Scholar 

  33. Gril B, Palmieri D, Qian Y, Anwar T, Ileva L, Bernardo M, Choyke P, Liewehr DJ, Steinberg SM, Steeg PS (2011) The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One 6(10):e25625

    Article  PubMed  CAS  Google Scholar 

  34. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98(6):1904–1913

    Article  PubMed  CAS  Google Scholar 

  35. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7(5):575–583

    Article  PubMed  CAS  Google Scholar 

  36. Maloney SL, Sullivan DC, Suchting S, Herbert JM, Rabai EM, Nagy Z, Barker J, Sundar S, Bicknell R (2009) Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane. Br J Cancer 101(6):957–966

    Article  PubMed  CAS  Google Scholar 

  37. Phipps C, Kohandel M (2011) Mathematical model of the effect of interstitial fluid pressure on angiogenic behavior in solid tumors. Comput Math Methods Med 2011:843765

    Article  PubMed  Google Scholar 

  38. Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F (2011) Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 9(Suppl 1):306–315

    Article  PubMed  Google Scholar 

  39. Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh VW (2000) Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60(21):6196–6200

    PubMed  CAS  Google Scholar 

  40. Elice F, Rodeghiero F, Falanga A, Rickles FR (2009) Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Hematol 22(1):115–128

    Article  PubMed  CAS  Google Scholar 

  41. Davis PJ, Davis FB, Mousa SA (2009) Thyroid hormone-induced angiogenesis. Curr Cardiol Rev 5(1):12–16

    Article  PubMed  CAS  Google Scholar 

  42. Mousa SA, Yalcin M, Bharali DJ, Meng R, Tang HY, Lin HY, Davis FB, Davis PJ (2012) Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76(1):39–45

    Article  PubMed  Google Scholar 

  43. Celgene Corporation (1998–2010) Thalidomide prescribing information. http://www.thalomid.com/. Accessed 8 April 2013

  44. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L (2005) Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103(1):119–125

    Article  PubMed  CAS  Google Scholar 

  45. McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS (2006) The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol 29(1):40–44

    Article  PubMed  CAS  Google Scholar 

  46. Celgene Corporation (2013) Revlimid prescribing information. http://www.revlimid.com/. Accessed 12 Mar 2013

  47. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142

    Article  PubMed  CAS  Google Scholar 

  48. Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 18(2):454–464

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA

    Shaker A. Mousa & Laila H. Anwar

Authors
  1. Shaker A. Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laila H. Anwar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaker A. Mousa .

Editor information

Editors and Affiliations

  1. , Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sc, Discovery Drive One, Rensselaer, 12144, New York, USA

    Shaker A. Mousa

  2. and Health Sciences, Pharmaceutical Research Institute, Albany College of Pharmacy, Discovery Drive 1, Rensselaer, 12144, New York, USA

    Paul J. Davis

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Mousa, S.A., Anwar, L.H. (2013). Anti-angiogenesis Therapy as an Adjunct to Chemotherapy in Oncology. In: Mousa, S., Davis, P. (eds) Angiogenesis Modulations in Health and Disease. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6467-5_12

Download citation

Publish with us

Policies and ethics

Search

Navigation